Endocrine Abstracts

Background: One of the most significant complications of type 2 diabetes (T2D) is non-alcoholic fatty liver disease (NAFLD). The search for new effective approaches to the treatment of patients with comorbid chronic condition such as type 2 diabetes and NAFLD is relevant.

Methods: We have observed 118 patients, including 64 patients with T2D and NAFLD, 26 patients with T2D and 28 patients with NAFLD. The control group consisted of 25 healthy individuals. Recommended treatment included individualized diet therapy with energy value of daily ration 1800–2300 kcal/day, a hepatoprotective salt of arginine and glutamic acid at 0.75 mg 3 times a day and alive multistrain probiotic at 10 mg twice a day. Clinical manifestations, echography semiotics, protein, lipid, enzyme and carbohydrate metabolism, the degree of IR, subpopulations of lymphocytes and interleukins, IgG antibodies to LPS, the range of average weight molecules, circulating immune complexes (CIC), dysbiotic disorders of the intestine in patients with T2D and NAFLD were studied.

Results: The application of the developed medical complex that included individualized diet, the salt of arginine and glutamic acid and a multiprobiotic contributed to the normalization of lipid, enzyme, carbohydrate metabolism, improvement of cellular and humoral links of the immune system, reducing levels of CIC 58.3%, reduction of endogenous intoxication (level MCM254 – 30.5%, MCM280 – by 32.4% and the level of IgG antibodies to LPS in 1,6 times), improvement of intestinal microbiocenosis in 84.4% of patients with T2D with NAFLD and normalization of pathological clinical manifestations in 68.8% of patients.

Conclusions: This study revealed the effects of proposed treatment complex on the major lymphocyte subpopulations and cytokine status, reduction of endotoxemia, promotion of the positive dynamics of lipid and carbohydrate metabolism indicators and intestinal microbiocenosis of patients with T2D and NAFLD.